Günter U Höglinger Selected Research

annonacin

1/2017	PERK activation mitigates tau pathology in vitro and in vivo.
11/2016	Chronic consumption of Annona muricata juice triggers and aggravates cerebral tau phosphorylation in wild-type and MAPT transgenic mice.
3/2014	Annonacin, a natural lipophilic mitochondrial complex I inhibitor, increases phosphorylation of tau in the brain of FTDP-17 transgenic mice.
11/2009	Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies.
7/2007	Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons.
1/2004	Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Günter U Höglinger Research Topics

Disease

40	Parkinson Disease (Parkinson's Disease) 02/2024 - 09/2003
29	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 12/2023 - 11/2005
21	Tauopathies 02/2024 - 11/2005
20	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2023 - 11/2005
12	Alzheimer Disease (Alzheimer's Disease) 04/2024 - 12/2011
9	Parkinsonian Disorders (Parkinsonism) 11/2023 - 01/2004
8	Disease Progression 01/2024 - 10/2013
8	Synucleinopathies 01/2023 - 07/2014
7	Multiple System Atrophy 11/2023 - 01/2017
6	Atrophy 09/2023 - 04/2014
6	Corticobasal Degeneration 12/2021 - 01/2018
4	Neuroinflammatory Diseases 01/2024 - 12/2020
3	Prodromal Symptoms 11/2023 - 01/2019
3	Movement Disorders (Movement Disorder) 08/2021 - 01/2020
3	Cerebellar Ataxia (Dysmetria) 01/2019 - 02/2016
2	Dementia (Dementias) 11/2023 - 01/2017
2	Amyloidosis 10/2021 - 01/2021
2	Glioma (Gliomas) 05/2021 - 01/2014
2	Chronic Obstructive Pulmonary Disease (COPD) 01/2020 - 01/2019
2	Brain Diseases (Brain Disorder) 01/2020 - 12/2011
2	Schizophrenia (Dementia Praecox) 12/2011 - 06/2011
1	Obesity 01/2024
1	Clinical Deterioration 01/2024
1	Macular Degeneration (Age-Related Maculopathy) 12/2023
1	Nausea 01/2023
1	REM Sleep Behavior Disorder 01/2023
1	Constipation 01/2023
1	Heart Arrest (Cardiac Arrest) 01/2023
1	Critical Illness (Critically Ill) 09/2022
1	Panic Disorder (Panic Attack) 01/2022
1	Confusion (Bewilderment) 01/2022
1	Hypokinesia (Bradykinesia) 01/2022
1	Pick Disease of the Brain (Pick's Disease) 12/2021
1	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 12/2021
1	Pantothenate Kinase-Associated Neurodegeneration (Hallervorden-Spatz Disease) 07/2021
1	Nervous System Heredodegenerative Disorders 07/2021
1	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2021
1	Migraine Disorders (Migraine) 01/2020
1	Coronary Disease (Coronary Heart Disease) 01/2020
1	Heart Diseases (Heart Disease) 01/2020
1	Myocardial Infarction 01/2020

Drug/Important Bio-Agent (IBA)

17	Biomarkers (Surrogate Marker)IBA 01/2024 - 10/2013
11	SynucleinsIBA 04/2024 - 02/2016
10	tau Proteins (tau Protein)IBA 12/2023 - 11/2005
8	Proteins (Proteins, Gene)FDA Link 01/2024 - 02/2016
8	alpha-SynucleinIBA 07/2022 - 11/2005
6	Amyloid (Amyloid Fibrils)IBA 01/2024 - 01/2021
6	Levodopa (L Dopa)FDA LinkGeneric 01/2022 - 10/2013
6	annonacinIBA 01/2017 - 01/2004
5	Protein Isoforms (Isoforms)IBA 11/2021 - 12/2011
4	Dopamine (Intropin)FDA LinkGeneric 02/2024 - 07/2004
4	MicroRNAs (MicroRNA)IBA 01/2023 - 01/2021
4	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 12/2021 - 11/2016
4	tideglusibIBA 01/2017 - 04/2014
4	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 05/2015 - 01/2010
3	Glucose (Dextrose)FDA LinkGeneric 11/2023 - 01/2021
3	Glucosylceramidase (Glucocerebrosidase)IBA 01/2023 - 09/2015
3	AntibodiesIBA 10/2022 - 01/2021
3	LigandsIBA 01/2021 - 07/2017
3	davunetideIBA 01/2017 - 07/2014
3	Oxidopamine (6 Hydroxydopamine)IBA 05/2015 - 03/2008
2	Amyloid beta-PeptidesIBA 04/2024 - 12/2021
2	gosuranemabIBA 11/2023 - 01/2021
2	Monoclonal AntibodiesIBA 11/2023 - 01/2021
2	DNA (Deoxyribonucleic Acid)IBA 09/2023 - 01/2014
2	venglustatIBA 01/2023 - 01/2022
2	tilavonemabIBA 10/2021 - 01/2021
2	PesticidesIBA 01/2020 - 11/2018
2	Phosphotransferases (Kinase)IBA 01/2017 - 08/2015
2	NeurotoxinsIBA 01/2017 - 01/2008
2	Dopamine Agonists (Dopamine Agonist)IBA 09/2015 - 10/2013
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 05/2015 - 12/2012
2	Glycogen Synthase (Synthase I)IBA 04/2014 - 04/2014
2	Neuregulin-1 (Neuregulin 1)IBA 12/2012 - 06/2011
2	neuromelaninIBA 02/2011 - 01/2007
2	AcetogeninsIBA 07/2007 - 01/2004
1	Apolipoproteins E (ApoE)IBA 12/2023
1	Glycoproteins (Glycoprotein)IBA 01/2023
1	ceramide glucosyltransferaseIBA 01/2023
1	AcidsIBA 01/2023
1	Untranslated RNA (Noncoding RNA)IBA 11/2022
1	Piwi-Interacting RNAIBA 11/2022
1	Transfer RNA (tRNA)IBA 11/2022
1	GlycosphingolipidsIBA 01/2022
1	Glucosylceramides (Glucocerebrosides)IBA 01/2022
1	Cholinergic Agents (Cholinergics)IBA 01/2022
1	Neuroprotective AgentsIBA 10/2021
1	IronIBA 07/2021
1	Prescription DrugsIBA 01/2021
1	Biocompatible Materials (Biomaterials)IBA 01/2021
1	ParaffinIBA 01/2021
1	Formaldehyde (Formol)FDA Link 01/2021
1	Protein AggregatesIBA 01/2021
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2021

Therapy/Procedure

12	Therapeutics 05/2021 - 10/2007
3	Activities of Daily Living (ADL) 01/2023 - 01/2020
2	Drug Therapy (Chemotherapy) 01/2019 - 01/2019
1	Neurological Rehabilitation 09/2022
1	Aftercare (After-Treatment) 10/2021
1	Immunotherapy 08/2021